Efficacy and Safety of Guselkumab, an Anti–interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Dermatology"
DOI: 10.1001/jamadermatol.2017.5937
Abstract: Importance Palmoplantar pustulosis (PPP) is a recalcitrant skin disease with no biologics currently approved for treatment. The involvement of interleukin 23 (IL-23) and cytokines of the type 17 helper T cell lineage in the pathogenesis… read more here.
Keywords: week; trial; safety; group ... See more keywords
Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: A Phase 3 Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2019 at "JAMA dermatology"
DOI: 10.1001/jamadermatol.2019.1394
Abstract: Importance Palmoplantar pustulosis (PPP) causes erythematous, scaly plaques with recurrent sterile pustules refractory to treatment and with few randomized clinical trials conducted. Evidence points to involvement of interleukin 23 in the pathogenesis of PPP. Objective… read more here.
Keywords: dermatology; safety; group; randomized clinical ... See more keywords
A comprehensive evaluation of exposure–response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Pharmacokinetics and Pharmacodynamics"
DOI: 10.1007/s10928-018-9581-1
Abstract: Guselkumab, a human IgG1 monoclonal antibody that blocks interleukin-23, has been evaluated in one Phase 2 and two Phase 3 trials in patients with moderate-to-severe psoriasis, in which disease severity was assessed using Psoriasis Area… read more here.
Keywords: exposure response; response; guselkumab dose; evaluation ... See more keywords
Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Clinical Dermatology"
DOI: 10.1007/s40257-018-0396-z
Abstract: BackgroundHealth-related quality of life (HRQoL) may be markedly impaired in patients with moderate-to-severe psoriasis.ObjectivesOur objectives were to compare improvements in Dermatology Life Quality Index (DLQI) and Psoriasis Symptoms and Signs Diary (PSSD) scores between patients… read more here.
Keywords: week; dermatology; dlqi; psoriasis ... See more keywords
Comparaison de l’ixékizumab et du guselkumab : réponses cliniques sur 24 semaines et données sur l’expression des gènes sur 4 semaines
Sign Up to like & getrecommendations! Published in 2020 at "Annales De Dermatologie Et De Venereologie"
DOI: 10.1016/j.annder.2020.09.546
Abstract: Introduction L’objectif de l’etude IXORA-R etait de comparer l’efficacite de l’antagoniste de l’interleukine (IL)-17A, l’ixekizumab (IXE), et de l’inhibiteur de l’IL-23p19, le guselkumab (GUS), sur une periode de 24 semaines de traitement. Dans IXORA-R, le pourcentage de… read more here.
Keywords: par; ixe; sur semaines; expression des ... See more keywords
Maintenance of clinical response and consistent safety profile with up to three years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2019.11.040
Abstract: BACKGROUND Long-term maintenance treatment is required for patients with psoriasis. OBJECTIVES To evaluate the efficacy and safety of guselkumab in patients with moderate-to-severe psoriasis through three years of treatment. METHODS In two on-going, phase 3… read more here.
Keywords: three years; treatment; safety; voyage voyage ... See more keywords
Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of pharmaceutical and biomedical analysis"
DOI: 10.1016/j.jpba.2020.113433
Abstract: Therapeutic drug monitoring, which is the measurement of drug concentrations in the blood, is a useful tool to guide clinical decision-making and treatment adjustments, on the condition that drug concentrations are correlated with treatment response.… read more here.
Keywords: guselkumab anti; drug; anti guselkumab; moderate severe ... See more keywords
Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2019.1679336
Abstract: Abstract Introduction In VOYAGE 1 (NCT02207231) and VOYAGE 2 (NCT02207244), guselkumab, an interleukin-23 blocker, was safe and effective in patients with moderate-to-severe plaque psoriasis. Methods Patients who self-identified as Hispanic (n = 117) or non-Hispanic (n = 1686) were… read more here.
Keywords: treatment; non hispanic; voyage; hispanic non ... See more keywords
A safety evaluation of guselkumab for the treatment of psoriasis
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2018.1488963
Abstract: ABSTRACT Introduction: Guselkumab is a fully human monoclonal IgG1λ antibody for the treatment of plaque psoriasis that inhibits interleukin (IL)-23p19 subunit, reducing the proliferation of type 17 helper T (Th-17) cells and thus production of… read more here.
Keywords: evaluation guselkumab; treatment; safety evaluation; psoriasis ... See more keywords
Resolution of Enthesitis by Guselkumab and Relationships to Disease Burden: 1-Year Results of Two Phase-3 Psoriatic Arthritis Studies.
Sign Up to like & getrecommendations! Published in 2021 at "Rheumatology"
DOI: 10.1093/rheumatology/keab285
Abstract: OBJECTIVE To further characterize the effect of guselkumab, a selective interleukin-23p19-subunit inhibitor approved for psoriatic arthritis (PsA), on enthesitis and assess relationships between enthesitis resolution and patient status/outcomes. METHODS Adults with active PsA despite standard… read more here.
Keywords: psoriatic arthritis; resolution; enthesitis; disease ... See more keywords
Successful use of guselkumab in the treatment of severe hidradenitis suppurativa
Sign Up to like & getrecommendations! Published in 2020 at "Clinical and Experimental Dermatology"
DOI: 10.1111/ced.14199
Abstract: Hidradenitis Suppurativa (HS) is a chronic incurable disease of apocrine gland-bearing skin characterised by double comedones, recurrent nodules, draining tracts and scarring predominantly in the axilla, groin and inframammary folds. Adalimumab and Infliximab are recommended… read more here.
Keywords: treatment; guselkumab; hidradenitis suppurativa; use ... See more keywords